Paxil Tapering Guide
paroxetine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Paroxetine is an SSRI with notable anticholinergic activity, approved for major depressive disorder, OCD, panic disorder, social anxiety disorder, GAD, and PTSD. It is widely recognized as one of the more difficult SSRIs to discontinue.
10mg, 20mg, 30mg, 40mg
Tablets: 10mg, 20mg, 30mg, 40mg; Oral suspension: 10mg/5mL; Controlled-release (CR) tablets: 12.5mg, 25mg, 37.5mg
Category D (positive evidence of risk — cardiac malformations)
Mechanism of Action
Potent and selective inhibitor of serotonin reuptake (SERT). Also has significant anticholinergic (muscarinic) activity and weak norepinephrine reuptake inhibition, which contribute to its withdrawal profile.
Taper Notes
Short half-life for an SSRI. Liquid formulation available. Often considered one of the harder SSRIs to taper.
Hyperbolic Tapering Guidance
Particularly difficult to stop due to short half-life and anticholinergic withdrawal. Very slow final taper essential.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 4-6 weeks | Use available tablet strengths. Anticholinergic rebound may begin in this phase. |
| Middle reductions | 6-8 weeks | Ask your prescriber about liquid suspension or CR tablets for smoother transitions. |
| Lower dose reductions | 6-8 weeks | Paroxetine's non-linear kinetics mean even small changes can have an outsized effect. Go slow. |
| Final reductions | 8-16 weeks | Liquid formulation is often necessary for precise adjustments. Work closely with your prescriber. |
Withdrawal Timeline
12-24 hours after missed dose (shortest onset of all SSRIs)
2-5 days
2-6 weeks for most symptoms
Electric shock sensations, emotional lability, and derealization can persist 2-6 months. Paxil has the highest rate of protracted withdrawal among SSRIs.
Community Tips
Practical insights shared by members tapering Paxil. Not medical advice — always consult your prescriber.
- 1Ask your prescriber about Paxil liquid suspension — tablets crumble unevenly at lower doses.
- 2Paroxetine inhibits its own metabolism, so dose reductions at lower doses can feel larger than expected. Discuss this with your prescriber.
- 3Anticholinergic rebound (sweating, GI cramping, vivid dreams) is unique to Paxil among SSRIs. These symptoms resolve but can be alarming.
- 4If considering switching formulations (CR to IR), discuss equivalent dosing with your prescriber — they are not 1:1.
- 5Many members report Paxil as the hardest SSRI to stop. A fluoxetine cross-taper is an option but should be carefully considered with your prescriber given its complexity.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (serotonin syndrome risk)
- Thioridazine — contraindicated (QT prolongation via CYP2D6 inhibition)
- Pimozide — contraindicated
Food Interactions
- No significant food effect on absorption
- Avoid alcohol during treatment
Contraindications
- MAOIs within 14 days
- Thioridazine
- Pimozide
Toxicity
Serotonin syndrome risk. Anticholinergic toxicity at high doses. Associated with higher rates of discontinuation syndrome than other SSRIs.
Pharmacokinetics
ADME Profile
Completely absorbed after oral dosing but extensive first-pass metabolism reduces bioavailability to ~50%. Tmax ~5 hours. Food does not significantly affect absorption.
~8.7 L/kg
Extensively metabolized hepatically via CYP2D6 (primary) with CYP3A4 contribution. Paroxetine inhibits its own metabolism (CYP2D6 saturation), leading to non-linear pharmacokinetics.
Renal (~64% as metabolites, ~2% unchanged) and fecal (~36%).
~93–95%
Non-linear; clearance decreases at higher doses due to CYP2D6 saturation.
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Paxil (paroxetine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.